Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide
Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
Diabetic neuropathic pain is a common clinical manifestation of diabetic neuropathy, which
seriously affects the quality of life of patients. The clinical treatment is limited and the
curative effect is not good. In the previous animal studies, investigators found that the
change of pain threshold in diabetic rats showed a staged change, and was significantly
related to the change of brain microglia activity. It was confirmed that liraglutide could
regulate the activation of microglia in vitro. Then investigators found that it could
intervene diabetic neuropathic pain through the intervention of liraglutide in diabetic rats.
In the early stage of clinical observation, the investigators also preliminarily observed
that liraglutide can intervene diabetic neuropathic pain. At present, liraglutide is a
commonly used hypoglycemic drug in clinic. Therefore, on the basis of previous studies, this
study intends to select diabetic neuropathic pain patients whose blood sugar is not up to the
standard, and give Mecobalamin to treat diabetic neuropathy. In addition, on the basis of the
original hypoglycemic treatment, participants are randomly divided into one group to give
liraglutide, one group to increase or adjust insulin, with similar blood glucose level. The
improvement of diabetic neuropathic pain was observed. The aim of this study was to evaluate
the safety and efficacy of liraglutide in improving diabetic neuropathic pain.